Cargando…

Therapy Discontinuation after Myocardial Infarction

The discontinuation of recommended therapy after myocardial infarction predisposes patients to serious thrombotic complications. The aim of this study was a comprehensive analysis of permanent as well as short- and long-term discontinuation of pharmacotherapy, taking into consideration the basic gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Pietrzykowski, Łukasz, Kasprzak, Michał, Michalski, Piotr, Kosobucka, Agata, Fabiszak, Tomasz, Kubica, Aldona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766090/
https://www.ncbi.nlm.nih.gov/pubmed/33352811
http://dx.doi.org/10.3390/jcm9124109
_version_ 1783628635982266368
author Pietrzykowski, Łukasz
Kasprzak, Michał
Michalski, Piotr
Kosobucka, Agata
Fabiszak, Tomasz
Kubica, Aldona
author_facet Pietrzykowski, Łukasz
Kasprzak, Michał
Michalski, Piotr
Kosobucka, Agata
Fabiszak, Tomasz
Kubica, Aldona
author_sort Pietrzykowski, Łukasz
collection PubMed
description The discontinuation of recommended therapy after myocardial infarction predisposes patients to serious thrombotic complications. The aim of this study was a comprehensive analysis of permanent as well as short- and long-term discontinuation of pharmacotherapy, taking into consideration the basic groups of medications and nonadherence determinants in a one-year follow-up in post-myocardial infarction (MI) patients. Material and methods: The study was a single center cohort clinical trial with a one-year follow-up including 225 patients (73.3% men, 26.7% women) aged 62.9 ± 11.9 years. In eight cases (3.6%), the follow-up duration was less than one year due to premature death. The following factors were analyzed: lack of post-discharge therapy initiation; short-term therapy discontinuation (<30 days); long-term therapy discontinuation (≥30 days); and permanent cessation of therapy. The analysis of therapy discontinuation was performed based on prescription filling data. Results: Occupational activity (Odds Ratio (OR) 5.15; 95% Confidence interval (CI) 1.42–18.65; p = 0.013) and prior MI (OR 5.02; 95% CI 1.45–16.89; p = 0.009) were found to be independent predictors of a lack of post-discharge therapy initiation with P2Y(12) receptor inhibitors. We found no independent predictors of lack of post-discharge therapy initiation with other medications, whether analyzed separately or together. Age above 65 years (Hazard Ratio (HR)—1.59; 95% CI 1.15–2.19; p = 0.0049) and prior revascularization (HR—1.44; 95% CI 1.04–2.19; p = 0.0273) were identified as independent predictors of therapy discontinuation. Multilogistic regression analysis showed no independent predictors of the cessation of any of the medications as well as the permanent or temporary simultaneous discontinuation of all medications. Conclusions: The vast majority of post-MI patients discontinue, either temporarily or permanently, one of the essential medications within one year following myocardial infarction. The most likely medication class to be discontinued are statins. Older age and prior cardiac revascularization are independent determinants of therapy discontinuation.
format Online
Article
Text
id pubmed-7766090
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77660902020-12-28 Therapy Discontinuation after Myocardial Infarction Pietrzykowski, Łukasz Kasprzak, Michał Michalski, Piotr Kosobucka, Agata Fabiszak, Tomasz Kubica, Aldona J Clin Med Article The discontinuation of recommended therapy after myocardial infarction predisposes patients to serious thrombotic complications. The aim of this study was a comprehensive analysis of permanent as well as short- and long-term discontinuation of pharmacotherapy, taking into consideration the basic groups of medications and nonadherence determinants in a one-year follow-up in post-myocardial infarction (MI) patients. Material and methods: The study was a single center cohort clinical trial with a one-year follow-up including 225 patients (73.3% men, 26.7% women) aged 62.9 ± 11.9 years. In eight cases (3.6%), the follow-up duration was less than one year due to premature death. The following factors were analyzed: lack of post-discharge therapy initiation; short-term therapy discontinuation (<30 days); long-term therapy discontinuation (≥30 days); and permanent cessation of therapy. The analysis of therapy discontinuation was performed based on prescription filling data. Results: Occupational activity (Odds Ratio (OR) 5.15; 95% Confidence interval (CI) 1.42–18.65; p = 0.013) and prior MI (OR 5.02; 95% CI 1.45–16.89; p = 0.009) were found to be independent predictors of a lack of post-discharge therapy initiation with P2Y(12) receptor inhibitors. We found no independent predictors of lack of post-discharge therapy initiation with other medications, whether analyzed separately or together. Age above 65 years (Hazard Ratio (HR)—1.59; 95% CI 1.15–2.19; p = 0.0049) and prior revascularization (HR—1.44; 95% CI 1.04–2.19; p = 0.0273) were identified as independent predictors of therapy discontinuation. Multilogistic regression analysis showed no independent predictors of the cessation of any of the medications as well as the permanent or temporary simultaneous discontinuation of all medications. Conclusions: The vast majority of post-MI patients discontinue, either temporarily or permanently, one of the essential medications within one year following myocardial infarction. The most likely medication class to be discontinued are statins. Older age and prior cardiac revascularization are independent determinants of therapy discontinuation. MDPI 2020-12-19 /pmc/articles/PMC7766090/ /pubmed/33352811 http://dx.doi.org/10.3390/jcm9124109 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pietrzykowski, Łukasz
Kasprzak, Michał
Michalski, Piotr
Kosobucka, Agata
Fabiszak, Tomasz
Kubica, Aldona
Therapy Discontinuation after Myocardial Infarction
title Therapy Discontinuation after Myocardial Infarction
title_full Therapy Discontinuation after Myocardial Infarction
title_fullStr Therapy Discontinuation after Myocardial Infarction
title_full_unstemmed Therapy Discontinuation after Myocardial Infarction
title_short Therapy Discontinuation after Myocardial Infarction
title_sort therapy discontinuation after myocardial infarction
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766090/
https://www.ncbi.nlm.nih.gov/pubmed/33352811
http://dx.doi.org/10.3390/jcm9124109
work_keys_str_mv AT pietrzykowskiłukasz therapydiscontinuationaftermyocardialinfarction
AT kasprzakmichał therapydiscontinuationaftermyocardialinfarction
AT michalskipiotr therapydiscontinuationaftermyocardialinfarction
AT kosobuckaagata therapydiscontinuationaftermyocardialinfarction
AT fabiszaktomasz therapydiscontinuationaftermyocardialinfarction
AT kubicaaldona therapydiscontinuationaftermyocardialinfarction